Chabiotech Co.,Ltd.

KOSDAQ 085660.KQ

Chabiotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2023: 28.97%

Chabiotech Co.,Ltd. Gross Profit Margin is 28.97% for the year ending December 31, 2023, a 29.35% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Chabiotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2022 was 22.40%, a -20.47% change year over year.
  • Chabiotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2021 was 28.16%, a 4.34% change year over year.
  • Chabiotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2020 was 26.99%, a -14.72% change year over year.
  • Chabiotech Co.,Ltd. Gross Profit Margin for the year ending December 31, 2019 was 31.65%, a -5.37% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
KOSDAQ: 085660.KQ

Chabiotech Co.,Ltd.

CEO Hoon Oh Sang
IPO Date Feb. 10, 2009
Location South Korea
Headquarters 442 Dosan-daero
Employees 271
Sector Health Care
Industries
Description

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare. In addition, the company develops immune cells, such as CBT101 for recurrent glioblastoma and solid cancer, and CBT111 and CAR-NK for solid cancer; and stem cells, including CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for macular degeneration and Stargardt's disease. Further, it offers IVF (fertility) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; research services; and other services. The company was founded in 2002 and is headquartered in Seoul, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email